• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Daiichi Sankyo Company, Ltd - Product Pipeline Review - H2 2011 Product Image

Daiichi Sankyo Company, Ltd - Product Pipeline Review - H2 2011

  • ID: 1964404
  • November 2011
  • 338 pages
  • Global Markets Direct

Daiichi Sankyo Company, Ltd – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Daiichi Sankyo Company, Ltd - Product Pipeline Review - H2 2011” provides data on the Daiichi Sankyo Company, Ltd’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Daiichi Sankyo Company, Ltd’s corporate website, SEC filings, investor presentations and featured press releases, both from Daiichi Sankyo Company, Ltd and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Daiichi Sankyo Company, Ltd - Brief Daiichi Sankyo Company, Ltd overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Daiichi Sankyo Company, Ltd human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage READ MORE >



List of Tables
List of Figures
Daiichi Sankyo Company, Ltd Snapshot
Daiichi Sankyo Company, Ltd Overview
Key Information
Key Facts
Daiichi Sankyo Company, Ltd – Research and Development Overview
Key Therapeutic Areas
Daiichi Sankyo Company, Ltd – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Daiichi Sankyo Company, Ltd – Pipeline Products Glance
Daiichi Sankyo Company, Ltd – Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Daiichi Sankyo Company, Ltd Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Daiichi Sankyo Company, Ltd–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Daiichi Sankyo Company, Ltd – Drug Profiles
AMG 888
Product Description
Mechanism of Action
R&D Progress
CS-0777
Product Description
Mechanism of Action
R&D Progress
CS-1008
Product Description
Mechanism of Action
R&D Progress
Lixiana
Product Description
Mechanism of Action
R&D Progress
Nimotuzumab + Cisplatin + Vinorelbine + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
Nuclear Receptor Program
Product Description
Mechanism of Action
R&D Progress
Olmetec
Product Description
Mechanism of Action
R&D Progress
PLX-204
Product Description
Mechanism of Action
R&D Progress
PLX5622
Product Description
Mechanism of Action
R&D Progress
Protease Inhibitor
Product Description
Mechanism of Action
R&D Progress
SUN11031
Product Description
Mechanism of Action
R&D Progress
Taxoprexin
Product Description
Mechanism of Action
R&D Progress
TheraCIM
Product Description
Mechanism of Action
Tigatuzumab + Gemzar
Product Description
Mechanism of Action
R&D Progress
U3-1287 + Erlotinib
Product Description
Mechanism of Action
R&D Progress
U3-1784
Product Description
Mechanism of Action
R&D Progress
U3-1800
Product Description
Mechanism of Action
R&D Progress
Xgeva
Product Description
Mechanism of Action
XL550
Product Description
Mechanism of Action
R&D Progress
Daiichi Sankyo Company, Ltd – Pipeline Analysis
Daiichi Sankyo Company, Ltd – Pipeline Products by Therapeutic Class
Daiichi Sankyo Company, Ltd - Pipeline Products By Target
Daiichi Sankyo Company, Ltd – Pipeline Products by Route of Administration
Daiichi Sankyo Company, Ltd – Pipeline Products by Molecule Type
Daiichi Sankyo Company, Ltd – Recent Pipeline Updates
Daiichi Sankyo Company, Ltd - Dormant Projects
Daiichi Sankyo Company, Ltd - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
AJD101
CS-505
CS-758
CS-8080
SUN E7001
Carperitide
CS-003
DB-772d
Nefiracetam
Soblidotin + Gemcitabine
Daiichi Sankyo Company, Ltd – Company Statement
Daiichi Sankyo Company, Ltd – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Daiichi Sankyo Company, Ltd - Key Manufacturing Facilities
Recent Developments
Mar 31, 2011: BARDA Awards Advanced Development Contract To Biota For Development Of New Influenza Antiviral
Sep 28, 2011: Valeant Pharmaceuticals Receives Approval For Colesevelam Hydrochloride In Canada
Jul 19, 2011: Daiichi Sankyo Launches LIXIANA In Japan For Prevention Of Venous Thromboembolism After Major Orthopedic Surgery
May 19, 2011: Plexxikon Announces Presentation Of PLX3397 Data At ASCO 2011 Annual Meeting
May 17, 2011: Regency Therapeutics And Daiichi Sankyo Announce Launch And Commercial Availability Of SPRIX Nasal Spray
Sep 14, 2011: Daiichi Sankyo Receives Approval For Silodosin For Treatment Of Dysuria In China
Mar 08, 2011: Plexxikon Initiates Phase II Clinical Trial In Hodgkin Lymphoma With PLX3397
Apr 04, 2011: Pfizer Inc. (PFE) and Daiichi Sankyo, Inc. (D4S.F) Team Up in China
Aug 02, 2011: Daiichi Sankyo And Ranbaxy To Expand Hybrid Business Model In Mexico
Mar 01, 2011: Daiichi Sankyo To Leverage Ranbaxy’s Network To Market Innovative Products In Singapore
Financial Deals Landscape
Daiichi Sankyo Company, Ltd, Deals Summary
Daiichi Sankyo Company, Ltd, Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Ranbaxy Sells Its Vietnam Business
Ranbaxy Laboratories Acquires Dermatological Assets From Ochoa Laboratories
BioMimetic Therapeutics Sells Remaining Dental Business To Luitpold Pharmaceuticals
Ranbaxy Laboratories Acquires US Rights Of Dermatology Products From Bristol-Myers Squibb
Venture Financing
Intradigm Secures $18.5 Million In Series B Financing
U3 Pharma Secures $34 Million In Series C Financing
SymBio Pharmaceuticals Raises $9 Million In Series A Financing
Private Equity
ICICI Venture Acquires RFCL From Ranbaxy Laboratories
Partnerships
Divine Skin Enters Into Co-Marketing Agreement With Ranbaxy Laboratories
GlaxoSmithKline Enters Into Co-Promotion Agreement With Daiichi Sankyo
AstraZeneca Enters Into Co-Promotion Agreement With Daiichi Sankyo For Denosumab
Pfizer Enters Into Co-Promotion Agreement With Daiichi Sankyo For Benicar
Ranbaxy Laboratories Enters Into Co-Marketing Agreement With Daiichi Sankyo
AstraZeneca Enters Into Co-Promotion Agreement With Daiichi Sankyo For Eesomeprazole
KINAXO Biotechnologies Enters Into Research Collaboration With Daiichi Sankyo
Daiichi Sankyo Forms Joint Venture With Kitasato Institute Research
Daiichi Sankyo Enters Into Licensing Agreement With Apotex
Daiichi Sankyo Enters Into Licensing Agreement With BioWa And Lonza
Omeros Corporation Enters Into Licensing Agreement With Asubio Pharma
Ranbaxy Enters Into Licensing Agreement With Summit Pharmaceuticals
BioInvent International Enters Into Licensing Agreement With DAIICHI SANKYO
Dimethaid Enters Into Licensing Agreement With Ranbaxy Laboratories
Ranbaxy Laboratories Enters Into Licensing Agreement With Medy-Tox
ArQule Enters Into Licensing Agreement With Daiichi Sankyo
Ranbaxy Laboratories Enters Into Licensing Agreement With BioPro Pharmaceutical
Daiichi Sankyo Enters Into Licensing Agreement With Merck Serono
Fresenius Medical Care Enters Into Licensing Agreement With Luitpold Pharmaceuticals For Venofer
Fresenius Medical Enters Into A Licensing Agreement With Luitpold
Daiichi Sankyo Enters Into Licensing Agreement With Bristol-Myers Squibb For Mevalotin
Fresenius Medical Care Enters Into Licensing Agreement With Luitpold Pharmaceuticals For Injectafer
Seattle Genetics Enters Into Licensing Agreement With Daiichi Sankyo
Ranbaxy Laboratories Enters Into Licensing Agreement With Pfizer
Daiichi Sankyo Expands Licensing Agreement With MorphoSys
Ranbaxy Laboratories Enters Into Licensing Agreement With CD Pharma
Genta Enters Into Licensing Agreement With Daiichi Sankyo
BioMimetic Therapeutics Enters Into License Agreement With Luitpold Pharmaceuticals
Ranbaxy Laboratories Enters Into Licensing Agreement With Sirtex Medical
BioMarin Pharmaceutical Enters Into Licensing Agreement With Asubio Pharma
Daiichi Sankyo Enters Into Licensing Agreement With Amgen
Ranbaxy Laboratories Enters Into An Agreement With Jupiter Bioscience
Ranbaxy Laboratories Enters Into Licensing Agreement With Pharmaceutical Product Development
Ranbaxy Laboratories Enters Into Licensing Agreement With Debiopharm For Sanvar
Gilead Sciences Enters Into Licensing Agreement With Ranbaxy Laboratories
Ranbaxy Laboratories Enters Into Licensing Agreement With Ethypharm
Daiichi Pharmaceutical Enters Into Licensing Agreement With CIMYM BioSciences
Ranbaxy Laboratories Enters Into Licensing Agreement With Ethypharm India
Ranbaxy Laboratories Enters Into Licensing Agreement With Eurodrug For Doxophylline
Ingenuity Systems Expands Licensing Agreement With Daiichi Pharmaceutical
MorphoSys Enters Into Licensing Agreement With Daiichi Sankyo
Ranbaxy Laboratories Enters Into Licensing Agreement With Cephalon
Ranbaxy Laboratories Enters Into Licensing Agreement With Lupin
Ranbaxy Laboratories Enters Into Licensing Agreement With J. B. Chemicals & Pharmaceuticals
BioMarin Enters Into Licensing Agreement With Daiichi Suntory Pharma
Daewoong Pharmaceutical Enters Into Licensing Agreement With Daiichi Sankyo
BioMarin Enters Into Licensing Agreement With Daiichi Suntory Pharma For Phenoptin
Ranbaxy Laboratories Signs Licensing Agreement With Atrix Laboratories
Replidyne Enters Into Licensing Agreement With Daiichi Suntory Pharma
Equity Offering
Zenotech Laboratories Completes Private Placement Of $22 Million
Zenotech Laboratories Completes Private Placement Of $5 Million
Debt Offering
Daiichi Sankyo Completes Public Offering Of First Series Of Unsecured Straight Bonds For $656 Million
Daiichi Sankyo Completes Public Offering Of Second Series Of Unsecured Straight Bonds For $413 Million
Ranbaxy Laboratories Completes Private Placement Of Bonds For $440 Million
Asset Transactions
CMIC Acquires Shizuoka Plant From DAIICHI SANKYO PROPHARMA
Dade Behring Acquires Diagnostic Assets From Ranbaxy
Acquisition
Luitpold Pharmaceuticals Acquires Roxro Pharma
Toho Pharmaceutical Acquires Asucome
Ranbaxy Acquires Biovel Life sciences
Silence Therapeutics Completes Acquisition Of Intradigm
HNG Chembio Pharmacy Acquires Ranbaxy Guangzhou From Ranbaxy
Luitpold Pharmaceuticals Acquires PharmaForce
Ranbaxy Laboratories Sells Its 50% Stake In Nihon Pharmaceutical To Nippon Chemiphar
Daiichi Sankyo Acquires Solrex Pharmaceuticals
Daiichi Sankyo Acquires Ranbaxy Netherlands
Daiichi Sankyo Acquires Majority Stake In Ranbaxy Laboratories
Daiichi Sankyo Acquires U3 Pharma
Ranbaxy Laboratories Acquires Vectra Pharmaceuticals
Ranbaxy Laboratories Acquires 25.15% Stake In Zenotech Laboratories
Kyowa Hakko Acquires Daiichi Fine Chemical
Ranbaxy Sells 25% Stake In Be-Tabs Pharmaceuticals
Ranbaxy Acquires Be-Tabs Pharmaceuticals
Ranbaxy Laboratories Acquires Minority Stake In Jupiter Bioscience
Nipro Acquires Saitama Daiichi From Daiichi Sankyo
OHARA Pharmaceutical Acquires Sankyo Yell Yakuhin From Daiichi Sankyo
Ranbaxy Laboratories Acquires Stake In Shimal Reasearch Laboratories
Ranbaxy Laboratories Acquires Minority Stake In Krebs Biochemicals & Industries
QOL Acquires Daiichi Medical From Daiichi Pharmaceutical
Daiichi Pharmaceutical Acquires Daiichi Pharmaceutical Korea
FUJIFILM Acquires Daiichi Radioisotope From Daiichi Pharmaceutical
Ranbaxy Laboratories Acquires Cardinal Drugs
Ranbaxy Laboratories Acquires Terapia From Advent International, FMO And EBRD
Ranbaxy Acquires Ethimed
Daiichi Sankyo Acquires Zepharma From Astellas Pharma
Ranbaxy Laboratories Acquires Stake In Allen From GlaxoSmithKline
Ranbaxy Acquires Additional Minority Stake In Ranbaxy Farmaceutica
Ranbaxy Laboratories Acquires 40% Interest In Nihon Pharmaceutical Industry From NIPPON CHEMIPHAR
Daiichi Pharmaceutical Acquires Daiichi Suntory Pharma From Suntory
Ranbaxy Acquires Ranbaxy Pharmacie
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Daiichi Sankyo Company, Ltd – Pipeline by Therapy Area and Indication, H2 2011
Daiichi Sankyo Company, Ltd – Pipeline by Stage of Development, H2 2011
Daiichi Sankyo Company, Ltd – Monotherapy Products in Pipeline, H2 2011
Daiichi Sankyo Company, Ltd – Combination Treatment Modalities in Pipeline, H2 2011
Daiichi Sankyo Company, Ltd – Filed, H2 2011
Daiichi Sankyo Company, Ltd – Phase III, H2 2011
Daiichi Sankyo Company, Ltd - Phase II, H2 2011
Daiichi Sankyo Company, Ltd - Phase I, H2 2011
Daiichi Sankyo Company, Ltd - Pipeline By Therapeutic Class, H2 2011
Daiichi Sankyo Company, Ltd - Pipeline By Target, H2 2011
Daiichi Sankyo Company, Ltd – Pipeline By Route of Administration, H2 2011
Daiichi Sankyo Company, Ltd – Pipeline By Molecule Type, H2 2011
Daiichi Sankyo Company, Ltd – Recent Pipeline Updates, H2 2011
Daiichi Sankyo Company, Ltd - Dormant Developmental Projects, 2010
Daiichi Sankyo Company, Ltd - Discontinued Pipeline Products, 2010
Daiichi Sankyo Company, Ltd, Other Locations
Daiichi Sankyo Company, Ltd, Subsidiaries
Daiichi Sankyo Company, Ltd, Key Manufacturing Facilities
Daiichi Sankyo Company, Ltd, Deals Summary
Ranbaxy Sells Its Vietnam Business
Ranbaxy Laboratories Acquires Dermatological Assets From Ochoa Laboratories
BioMimetic Therapeutics Sells Remaining Dental Business To Luitpold Pharmaceuticals
Ranbaxy Laboratories Acquires US Rights Of Dermatology Products From Bristol-Myers Squibb
Intradigm Secures $18.5 Million In Series B Financing
U3 Pharma Secures $34 Million In Series C Financing
SymBio Pharmaceuticals Raises $9 Million In Series A Financing
ICICI Venture Acquires RFCL From Ranbaxy Laboratories
Divine Skin Enters Into Co-Marketing Agreement With Ranbaxy Laboratories
GlaxoSmithKline Enters Into Co-Promotion Agreement With Daiichi Sankyo
AstraZeneca Enters Into Co-Promotion Agreement With Daiichi Sankyo For Denosumab
Pfizer Enters Into Co-Promotion Agreement With Daiichi Sankyo For Benicar
Ranbaxy Laboratories Enters Into Co-Marketing Agreement With Daiichi Sankyo
AstraZeneca Enters Into Co-Promotion Agreement With Daiichi Sankyo For Eesomeprazole
KINAXO Biotechnologies Enters Into Research Collaboration With Daiichi Sankyo
Daiichi Sankyo Forms Joint Venture With Kitasato Institute Research
Daiichi Sankyo Forms Joint Venture With Sanofi Pasteur
Daiichi Sankyo And Sanofi Enter Into Distribution Agreement With Ranbaxy For Tavanic
Ranbaxy Laboratories Enters Into Co-Development Agreement With Pfenex
MorphoSys Enters Into Co-Development Agreement With DAIICHI SANKYO
Daewoong Pharmaceutical Enters Into Co-Marketing Agreement With Daiichi Sankyo
DAIICHI SANKYO Enters Into Agreement With Biota Holdings
Daiichi Sankyo Enters Alliance With The Kitasato Institute
ArQule Enters Into An Agreement With Daiichi Sankyo
Sanofi Pasteur Enters Into An Agreement With Daiichi Sankyo
Ranbaxy Laboratories Enters Into Co-Development Agreement With Merck
Ranbaxy Laboratories Enters Into An Agreement With Orchid Chemicals & Pharmaceuticals
Ranbaxy Laboratories Enters Into Agreement With Department of Biotechnology
Ranbaxy Laboratories Enters Into Co-Marketing Agreement With Virchow Biotech
Daiichi Sankyo Obtains Rights To EVISTA From Eli Lilly
Sanofi-Aventis Enters Into Co-Marketing Agreement With Daiichi
Ranbaxy Laboratories Enters Into Agreement With Zenotech Laboratories
Ranbaxy Laboratories Signs Co-Development Agreement With GlaxoSmithKline
Evotec Enters Into Co-Development Agreement With Daiichi Pharmaceutical
Daiichi Sankyo Partners With Eli Lilly
Ranbaxy Laboratories Enters Into Co-Marketing Agreement With InvaGen Pharmaceuticals
Exelixis Enters Into Co-Development Agreement With Sankyo
Ranbaxy Laboratories Enters Into Co-Marketing Agreement With Zenotech
Ranbaxy Laboratories Forms Joint Venture With Community Investment Holdings
Ranbaxy Laboratories Enters Into Co-Marketing Agreement With Ferring International
UCB Japan Enters Into Co-Promotion Agreement With Daiichi Pharmaceutical
Sanofi-Aventis Enters Into Co-Marketing Agreement With Daiichi Sankyo
Ranbaxy Enters Into Research Collaboration With NCL And DST
Cyntellect Enters Into Research Collaboration Agreement With Daiichi Pharmaceutical
Anadys Pharmaceuticals Enters Into Agreement With Daiichi Pharmaceutical
Aventis Pasteur Enters Into Co-Promotion Agreement With Ranbaxy Laboratories For Vaxigrip
Ranbaxy Laboratories Enters Into Research Agreement With Avesthagen
Ranbaxy Laboratories Enters Into Agreement With NIPER And DST
Tularik Extends Co-Development Agreement With Sankyo
BioMimetic Pharmaceuticals Enters Into Co-Development Agreement With Luitpold Pharmaceuticals
Daiichi Pharmaceutical Merges With Sankyo
Ranbaxy Enters Into Licensing Agreement With Takeda
Daiichi Sankyo Enters Into Licensing Agreement With Crucell And DSM Biologics
Celgene Enters Into Patent Licensing Agreement With Barr, Mylan Bertek, Ranbaxy And Roche
Cyclacel Pharmaceuticals Amends Its Licensing Agreement With Daiichi Sankyo For Sapacitabine
Gilead Sciences Extends Licensing Agreement With Ranbaxy Laboratories For Tenofovir, Elvitegravir, Cobicistat And Quad
Pieris Enters Into Collaboration And Licensing Agreement With Daiichi Sankyo
Omeros Expands Licensing Agreement With Daiichi Sankyo
ArQule Expands Its Licensing Agreement With Daiichi Sankyo
Daiichi Sankyo Enters Into Licensing Agreement With Apotex
Daiichi Sankyo Enters Into Licensing Agreement With BioWa And Lonza
Omeros Corporation Enters Into Licensing Agreement With Asubio Pharma
Ranbaxy Enters Into Licensing Agreement With Summit Pharmaceuticals
BioInvent International Enters Into Licensing Agreement With DAIICHI SANKYO
Dimethaid Enters Into Licensing Agreement With Ranbaxy Laboratories
Ranbaxy Laboratories Enters Into Licensing Agreement With Medy-Tox
ArQule Enters Into Licensing Agreement With Daiichi Sankyo
Ranbaxy Laboratories Enters Into Licensing Agreement With BioPro Pharmaceutical
Daiichi Sankyo Enters Into Licensing Agreement With Merck Serono
Fresenius Medical Care Enters Into Licensing Agreement With Luitpold Pharmaceuticals For Venofer
Fresenius Medical Enters Into A Licensing Agreement With Luitpold
Daiichi Sankyo Enters Into Licensing Agreement With Bristol-Myers Squibb For Mevalotin
Fresenius Medical Care Enters Into Licensing Agreement With Luitpold Pharmaceuticals For Injectafer
Seattle Genetics Enters Into Licensing Agreement With Daiichi Sankyo
Ranbaxy Laboratories Enters Into Licensing Agreement With Pfizer
Daiichi Sankyo Expands Licensing Agreement With MorphoSys
Ranbaxy Laboratories Enters Into Licensing Agreement With CD Pharma
Genta Enters Into Licensing Agreement With Daiichi Sankyo
BioMimetic Therapeutics Enters Into License Agreement With Luitpold Pharmaceuticals
Ranbaxy Laboratories Enters Into Licensing Agreement With Sirtex Medical
BioMarin Pharmaceutical Enters Into Licensing Agreement With Asubio Pharma
Daiichi Sankyo Enters Into Licensing Agreement With Amgen
Ranbaxy Laboratories Enters Into An Agreement With Jupiter Bioscience
Ranbaxy Laboratories Enters Into Licensing Agreement With Pharmaceutical Product Development
Ranbaxy Laboratories Enters Into Licensing Agreement With Debiopharm For Sanvar
Gilead Sciences Enters Into Licensing Agreement With Ranbaxy Laboratories
Ranbaxy Laboratories Enters Into Licensing Agreement With Ethypharm
Daiichi Pharmaceutical Enters Into Licensing Agreement With CIMYM BioSciences
Ranbaxy Laboratories Enters Into Licensing Agreement With Ethypharm India
Ranbaxy Laboratories Enters Into Licensing Agreement With Eurodrug For Doxophylline
Ingenuity Systems Expands Licensing Agreement With Daiichi Pharmaceutical
MorphoSys Enters Into Licensing Agreement With Daiichi Sankyo
Ranbaxy Laboratories Enters Into Licensing Agreement With Cephalon
Ranbaxy Laboratories Enters Into Licensing Agreement With Lupin
Ranbaxy Laboratories Enters Into Licensing Agreement With J. B. Chemicals & Pharmaceuticals
BioMarin Enters Into Licensing Agreement With Daiichi Suntory Pharma
Daewoong Pharmaceutical Enters Into Licensing Agreement With Daiichi Sankyo
BioMarin Enters Into Licensing Agreement With Daiichi Suntory Pharma For Phenoptin
Ranbaxy Laboratories Signs Licensing Agreement With Atrix Laboratories
Replidyne Enters Into Licensing Agreement With Daiichi Suntory Pharma
Zenotech Laboratories Completes Private Placement Of $22 Million
Zenotech Laboratories Completes Private Placement Of $5 Million
Daiichi Sankyo Completes Public Offering Of First Series Of Unsecured Straight Bonds For $656 Million
Daiichi Sankyo Completes Public Offering Of Second Series Of Unsecured Straight Bonds For $413 Million
Ranbaxy Laboratories Completes Private Placement Of Bonds For $440 Million
CMIC Acquires Shizuoka Plant From DAIICHI SANKYO PROPHARMA
Dade Behring Acquires Diagnostic Assets From Ranbaxy
Luitpold Pharmaceuticals Acquires Roxro Pharma
Toho Pharmaceutical Acquires Asucome
Ranbaxy Acquires Biovel Life sciences
Silence Therapeutics Completes Acquisition Of Intradigm
HNG Chembio Pharmacy Acquires Ranbaxy Guangzhou From Ranbaxy
Luitpold Pharmaceuticals Acquires PharmaForce
Ranbaxy Laboratories Sells Its 50% Stake In Nihon Pharmaceutical To Nippon Chemiphar
Daiichi Sankyo Acquires Solrex Pharmaceuticals
Daiichi Sankyo Acquires Ranbaxy Netherlands
Daiichi Sankyo Acquires Majority Stake In Ranbaxy Laboratories
Daiichi Sankyo Acquires U3 Pharma
Ranbaxy Laboratories Acquires Vectra Pharmaceuticals
Ranbaxy Laboratories Acquires 25.15% Stake In Zenotech Laboratories
Kyowa Hakko Acquires Daiichi Fine Chemical
Ranbaxy Sells 25% Stake In Be-Tabs Pharmaceuticals
Ranbaxy Acquires Be-Tabs Pharmaceuticals
Ranbaxy Laboratories Acquires Minority Stake In Jupiter Bioscience
Nipro Acquires Saitama Daiichi From Daiichi Sankyo
OHARA Pharmaceutical Acquires Sankyo Yell Yakuhin From Daiichi Sankyo
Ranbaxy Laboratories Acquires Stake In Shimal Reasearch Laboratories
Ranbaxy Laboratories Acquires Minority Stake In Krebs Biochemicals & Industries
QOL Acquires Daiichi Medical From Daiichi Pharmaceutical
Daiichi Pharmaceutical Acquires Daiichi Pharmaceutical Korea
FUJIFILM Acquires Daiichi Radioisotope From Daiichi Pharmaceutical
Ranbaxy Laboratories Acquires Cardinal Drugs
Ranbaxy Laboratories Acquires Terapia From Advent International, FMO And EBRD
Ranbaxy Acquires Ethimed
Daiichi Sankyo Acquires Zepharma From Astellas Pharma
Ranbaxy Laboratories Acquires Stake In Allen From GlaxoSmithKline
Ranbaxy Acquires Additional Minority Stake In Ranbaxy Farmaceutica
Ranbaxy Laboratories Acquires 40% Interest In Nihon Pharmaceutical Industry From NIPPON CHEMIPHAR
Daiichi Pharmaceutical Acquires Daiichi Suntory Pharma From Suntory
Ranbaxy Acquires Ranbaxy Pharmacie

List of Figures
Daiichi Sankyo Company, Ltd – Pipeline by Therapy Area and Indication, H2 2011
Daiichi Sankyo Company, Ltd – Pipeline by Stage of Development, H2 2011
Daiichi Sankyo Company, Ltd – Monotherapy Products in Pipeline, H2 2011
Daiichi Sankyo Company, Ltd – Combination Treatment Modalities in Pipeline, H2 2011
Daiichi Sankyo Company, Ltd – Pipeline By Therapeutic Class, H2 2011
Daiichi Sankyo Company, Ltd - Pipeline By Target, H2 2011
Daiichi Sankyo Company, Ltd – Pipeline By Route of Administration, H2 2011
Daiichi Sankyo Company, Ltd – Pipeline By Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos